Revolutionizing Skin Longevity: OneSkin Secures $7 Million in Funding for Breakthrough Anti-Aging Technology

OneSkin, a pioneering longevity company founded by a team of four visionary female PhDs, has successfully raised $7 million in a recent funding round aimed at advancing its innovative approach to skin health and aging. Committed to transforming societal perceptions of skin aging, OneSkin focuses on developing products that not only enhance beauty but also prioritize skin longevity. Central to their product line is the groundbreaking proprietary peptide, OS-01, which stands out as the first ingredient clinically designed to reduce the biological age of skin. Through its unique properties, OS-01 works to bolster the skin barrier, support critical DNA damage repair, and prevent the accumulation of aged cells—ultimately striving to promote a youthful and resilient complexion. The new funding will enable OneSkin to accelerate its research and development initiatives, refine its product offerings, and expand its reach in the rapidly growing longevity skincare market. As consumer demand for effective and science-backed skincare solutions continues to rise, OneSkin is poised to lead the charge in providing innovative, evidence-based products that empower individuals to take control of their skin’s aging process. With this latest investment, OneSkin aims to not only enhance the efficacy of its current products but also explore new avenues for scientific advancements in the field of skin health, solidifying its position as a frontrunner in the pursuit of ageless skin.